2021
Chemical complementarity between immune receptors and cancer mutants, independent of antigen presentation protein binding, is associated with increased survival rates
Hsiang M, Chobrutskiy BI, Diaz M, Huda TI, Creadore S, Zaman S, Cios KJ, Gozlan EC, Blanck G. Chemical complementarity between immune receptors and cancer mutants, independent of antigen presentation protein binding, is associated with increased survival rates. Translational Oncology 2021, 14: 101069. PMID: 33780706, PMCID: PMC8039726, DOI: 10.1016/j.tranon.2021.101069.Peer-Reviewed Original ResearchT cell receptor alpha geneAmino acidsT cell receptorChemical complementarityV-J recombinationMutant amino acidsThe Cancer Genome Atlas (TCGA) databaseCancer Genome Atlas (TCGA) databaseCancer mutantsBioinformatics approachAlpha geneReceptor alpha geneImmune receptorsComplement genesAtlas databaseMutantsPeptide sequencesSpecific interactionsGenesII bindingLRP2Region 3 sequencesUterine cancerProtein bindingBinding
2019
Potential MMP2-mediated availability of HLA binding, mutant ECM peptides reflects better melanoma survival rates and greater T-cell infiltrates
Zaman S, Chobrutskiy BI, Patel JS, Callahan BM, Mihyu MM, Diviney A, Blanck G. Potential MMP2-mediated availability of HLA binding, mutant ECM peptides reflects better melanoma survival rates and greater T-cell infiltrates. Laboratory Investigation 2019, 99: 1287-1295. PMID: 31019293, DOI: 10.1038/s41374-019-0248-3.Peer-Reviewed Original ResearchConceptsMutant amino acidsAmino acidsStructural proteinsExtracellular matrix structural proteinsMatrix metalloproteinase-2Cancer progressionLate-stage cancer developmentMutant peptidesECM structural proteinsMatrix structural proteinsBioinformatics approachProtein mutantsProtease functionECM peptidesSuch proteasesMutantsPotential substratesCancer developmentProteaseMelanoma samplesProteinSpread of cancerTumor samplesMetalloproteinase-2Cancer microenvironment